CardioSomaticsCardioSomaticsCardioСоматика2221-71852658-5707Eco-Vector63292710.17816/CS632927ReviewsОбзорыReview ArticleRole of inflammaging in the development of chronic heart failure and osteoporosis: A literature reviewРоль воспалительного старения в развитии хронической сердечной недостаточности и остеопороза: обзор литературыhttps://orcid.org/0000-0001-7825-55973674-9620LarinaVera N.ЛаринаВера Николаевна
Russian Federation

MD, Dr. Sci. (Medicine), professor

доктор мед. наук, профессор

larinav@mail.ruhttps://orcid.org/0000-0001-8619-81236888-5050ShcherbinaEkaterina S.ЩербинаЕкатерина Сергеевна
Russian Federation
semushinamarina@yandex.ruPirogov Russian National Research Medical UniversityРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова29082024151120241532312422805202425082024Copyright ©; 2024, Eco-VectorCopyright ©; 2024, ООО "Эко-Вектор"2024Eco-VectorООО "Эко-Вектор"https://creativecommons.org/licenses/by-nc-nd/4.0https://cardiosomatics.ru/2221-7185/article/view/632927

The interaction between heart failure (HF) and osteoporosis in a multimorbid patient is a relevant complication in the aging population. The concept of inflammaging (inflammatory aging) allows us to consider the prolonged process of subclinical inflammation as an adaptation. Depending on the positive or negative influence of inflammaging on the human body, it may induce healthy longevity or aging that is accompanied by geriatric syndromes and various pathologies, including HF and osteoporosis. In this review, we aimed to highlight the issue of inflammaging as a systemic factor in the development of HF and osteoporosis. The function of inflammatory markers, the role of the NLRP3 inflammasome in the immunoinflammatory pathway, and NLRP3’s role in the development of both HF and osteoporosis via the formation of proinflammatory cytokines have been discussed. The influence on different pathogeneses have been considered to determine the development of new therapies.

Проблема взаимосвязи хронической сердечной недостаточности (ХСН) и остеопороза у мультиморбидного пациента актуальна в свете старения населения. Концепция «inflammaging» (воспалительного старения) позволяет рассматривать продолжительный процесс субклинического воспаления как адаптацию. В зависимости от положительного или отрицательного влияния этого фактора на организм человека результатом может быть здоровое долголетие или старение, сопровождающееся гериатрическими синдромами и возникновением различных патологий, включая развитие ХСН и остеопороза. В данной статье освещена проблема воспалительного старения как системного фактора в контексте развития ХСН и остеопороза: обсуждается функция воспалительных маркеров, а также роль инфламмасомы NLRP3 в иммуновоспалительном пути развития как ХСН, так и остеопороза посредством влияния на формирование провоспалительных цитокинов. Рассматриваются способы влияния на различные звенья патогенеза, что может лежать в основе разработки новых методов терапии.

heart failureosteoporosisinflammagingсердечная недостаточностьостеопорозвоспалительное старениеOverview of Ageing. In: World Health Organization [Internet]. Available from: https://www.who.int/ru/health-topics/ageing#tab=tab_1 Accessed: 23.02.2024.Overview of Ageing. В: World Health Organization [Internet]. Режим доступа: https://www.who.int/ru/health-topics/ageing#tab=tab_1 Дата обращения: 23.02.2024.Decade of healthy ageing: baseline report, 2021. In: World Health Organization [Internet]. Available from: https://www.who.int/publicationsMem/9789240017900 Accessed: 23.02.2024.Decade of healthy ageing: baseline report, 2021. В: World Health Organization [Internet]. Режим доступа: https://www.who.int/publicationsMem/9789240017900 Дата обращения: 23.02.2024.Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:208–218. doi: 10.1111/j.1749-6632.2000.tb06651.xFranceschi C., Bonafe M., Valensin S., et al. Inflamm-aging. An evolutionary perspective on immunosenescence // Ann N Y Acad Sci. 2000. Vol. 908. Р. 208–218. doi: 10.1111/j.1749-6632.2000.tb06651.xSavarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–3287. doi: 10.1093/cvr/cvac013Savarese G., Becher P.M., Lund L.H., et al. Global burden of heart failure: a comprehensive and updated review of epidemiology // Cardiovasc Res. 2023. Vol. 118, N. 17. Р. 3272–3287. doi: 10.1093/cvr/cvac013Artemyeva OV, Gankovskaya LV, Inflammagingas the basis of age-associated diseases. Meditsinskaya Immunologiya. 2020;22(3):419–432. doi: 10.15789/1563-0625-IAT-1938Артемьева О.В., Ганковская Л.В. Воспалительное старение как основа возраст-ассоциированной патологии // Медицинская иммунология. 2020. Т. 22, № 3. С. 419–432. doi: 10.15789/1563-0625-IAT-1938.Artemyeva OV, Grechenko VV, Gromova TV, et al. Frailty: a controversial role of inflammaging. Immunologiya. 2022;43(6):746–56. doi: 10.33029/0206-4952-2022-43-6-746-756Артемьева О.В., Греченко В.В., Громова Т.В., и др. Синдром старческой астении: неоднозначная роль воспалительного старения // Иммунология. 2022. Т. 43, № 6. С. 746–756. doi: 10.33029/0206-4952-2022-43-6-746-756Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013;123(3):958–965. doi: 10.1172/JCI64096Montecino-Rodriguez E., Berent-Maoz B., Dorshkind K. Causes, consequences, and reversal of immune system aging // J Clin Invest. 2013. Vol. 123, N. 3. Р. 958–965. doi: 10.1172/JCI64096Bai L, Liu Y, Zhang X, et al. Osteoporosis remission via an anti-inflammaging effect by icariin activated autophagy. Biomaterials. 2023;297:122–125. doi: 10.1016/j.biomaterials.2023.122125Bai L., Liu Y., Zhang X., et al. Osteoporosis remission via an anti-inflammaging effect by icariin activated autophagy // Biomaterials. 2023. Vol. 297. Р. 122–125. doi: 10.1016/j.biomaterials.2023.122125DeBerge M, Shah SJ, Wilsbacher L, et al. Macrophages in heart failure with reduced versus preserved ejection fraction. Trends Mol Med. 2019;25(4):328–340. doi: 10.1016/j.molmed.2019.01.002DeBerge M., Shah S.J., Wilsbacher L., et al. Macrophages in heart failure with reduced versus preserved ejection fraction // Trends Mol Med. 2019. Vol. 25, N. 4. Р. 328–340. doi: 10.1016/j.molmed.2019.01.002Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728–741. doi: 10.1016/j.cell.2011.10.026Mizushima N., Komatsu M. Autophagy: renovation of cells and tissues // Cell. 2011. Vol. 147, N. 4. Р. 728–741. doi: 10.1016/j.cell.2011.10.026Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen. 2017;58(5):235–263. doi: 10.1002/em.22087Chatterjee N., Walker G.C. Mechanisms of DNA damage, repair, and mutagenesis // Environ Mol Mutagen. 2017. Vol. 58, N. 5. Р. 235–263. doi: 10.1002/em.22087Mezzaroma E, Toldo S, Farkas D, et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA. 2011;108(49):19725–19730. doi: 10.1073/pnas.1108586108Mezzaroma E., Toldo S., Farkas D., et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse // Proc Natl Acad Sci USA. 2011. Vol. 108, N. 49. Р. 19725–19730. doi: 10.1073/pnas.1108586108Hulsmans M, Sager HB, Roh JD, et al. Cardiac macrophages promote diastolic dysfunction. J Exp Med. 2018;215(2):423–440. doi: 10.1084/jem.20171274Hulsmans M., Sager H.B., Roh J.D., et al. Cardiac macrophages promote diastolic dysfunction // J Exp Med. 2018. Vol. 215, N. 2. Р. 423–440. doi: 10.1084/jem.20171274Liang Z, Zhang T, Liu H, et al. Inflammaging: The ground for sarcopenia? Exp Gerontol. 2022;68:111931. doi: 10.1016/j.exger.2022.111931Liang Z., Zhang T., Liu H., et al. Inflammaging: The ground for sarcopenia? // Exp Gerontol. 2022. Vol. 68. Р. 111931. doi: 10.1016/j.exger.2022.111931Antuña E, Cachán-Vega C, Bermejo-Millo JC, et al. Inflammaging: Implications in Sarcopenia. Int J Mol Sci. 2022;23(23):15039. doi: 10.3390/ijms232315039Antuña E., Cachán-Vega C., Bermejo-Millo J.C., et al. Inflammaging: Implications in Sarcopenia // Int J Mol Sci. 2022. Vol. 23, N. 23. Р. 15039. doi: 10.3390/ijms232315039Ajoolabady A, Pratico D, Vinciguerra M, et al. Inflammaging: mechanisms and role in the cardiac and vasculature. Trends Endocrinol Metab. 2023;34(6):373–387. doi: 10.1016/j.tem.2023.03.005Ajoolabady A., Pratico D., Vinciguerra M., et al. Inflammaging: mechanisms and role in the cardiac and vasculature // Trends Endocrinol Metab. 2023. Vol. 34, N. 6. Р. 373–387. doi: 10.1016/j.tem.2023.03.005Kazanova PV, Basieva MA, Shvartz VA. Immune remodeling in the pathogenesis of atrial fibrillation. Annaly aritmologii. 2023;20(2):119–130. doi: 10.15275/annaritmol.2023.2.7Казанова П.В., Басиева М.А., Шварц В.А. Иммунное ремоделирование в патогенезе фибрилляции предсердий // Анналы аритмологии. 2023. Т. 20, № 2. С. 119–130. doi: 10.15275/annaritmol.2023.2.7Yao Y, Yang M, Liu D, et al. Immune remodeling and atrial fibrillation. Front Physiol. 2022;13:927221. doi: 10.3389/fphys.2022.927221Yao Y., Yang M., Liu D., et al. Immune remodeling and atrial fibrillation // Front Physiol. 2022. Vol. 13. Р. 927221. doi: 10.3389/fphys.2022.927221Ionin VA, Barashkova EI, Zaslavskaya EL, et al. Biomarkers of inflammation, parameters characterizing obesity and cardiac remodeling in patients with atrial fibrillation and metabolic syndrome. Russian Journal of Cardiology. 2021;26(3):4343. doi: 10.15829/15604071-2021-4343Ионин В.А., Барашкова Е.И., Заславская Е.Л., и др. Биомаркеры воспаления, параметры, характеризующие ожирение и ремоделирование сердца, у пациентов с фибрилляцией предсердий и метаболическим синдромом // Российский кардиологический журнал. 2021. Т. 26, № 3. С. 4343. doi: 10.15829/15604071-2021-4343Santhanakrishnan R, Chong JP, Ng TP, et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail. 2012;14(12):1338–1347. doi: 10.1093/eurjhf/hfs130Santhanakrishnan R., Chong J.P., Ng T.P., et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction // Eur J Heart Fail. 2012. Vol. 14, N. 12. Р. 1338–1347. doi: 10.1093/eurjhf/hfs130Alieva AM, Reznik EV, Pinchuk TV, et al. Growth Differentiation Factor-15 (GDF-15) is a Biological Marker in Heart Failure. The Russian Archives of Internal Medicine. 2023;13(1):14–23. doi: 10.20514/2226-6704-2023-13-1-14-23Алиева А.М., Резник Е.В., Пинчук Т.В., и др. Фактор дифференцировки роста — 15 (GDF-15) как биологический маркер при сердечной недостаточности // Архивъ внутренней медицины. 2023. Т. 13, № 1. С. 14–23. doi: 10.20514/2226-6704-2023-13-1-14-23Bouabdallaoui N, Claggett B, Zile MR, et al. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2018;20(12):1701–1709. doi: 10.1002/ejhf.1301Bouabdallaoui N., Claggett B., Zile M.R., et al. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial // Eur J Heart Fail. 2018. Vol. 20, N. 12. Р. 1701–1709. doi: 10.1002/ejhf.1301Vitt KN, Kuzheleva EA, Tukish OV, et al. Low-intensity inflammation as a manifestation of comorbidity and a factor in the unfavorable clinical course of heart failure with preserved ejection fraction. Cardiovascular Therapy and Prevention. 2024;23(2):3847. doi: 10.15829/1728-8800-2024-3847Витт К.Н., Кужелева Е.А., Тукиш О.В., и др. Низкоинтенсивное воспаление как проявление коморбидности и фактор неблагоприятного клинического течения сердечной недостаточности с сохранённой фракцией выброса // Кардиоваскулярная терапия и профилактика. 2024. Т. 23, № 2. С. 3847. doi: 10.15829/1728-8800-2024-3847Ballak DB, Stienstra R, Tack CJ, et al. IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance. Cytokine. 2015;75(2):280–290. doi: 10.1016/j.cyto.2015.05.005Ballak D.B., Stienstra R., Tack C.J., et al. IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance // Cytokine. 2015. Vol. 75, N. 2. Р. 280–290. doi: 10.1016/j.cyto.2015.05.005Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017;13(11):633–643. doi: 10.1038/nrendo.2017.90Reilly S.M., Saltiel A.R. Adapting to obesity with adipose tissue inflammation // Nat Rev Endocrinol. 2017. Vol. 13, N. 11. Р. 633–643. doi: 10.1038/nrendo.2017.90Gao J, Xie Q, Wei T, et al. Nebivolol Improves Obesity-Induced Vascular Remodeling by Suppressing NLRP3 Activation. J Cardiovasc Pharmacol. 2019;73(5):326–333. doi: 10.1097/FJC.0000000000000667Gao J., Xie Q., Wei T., et al. Nebivolol Improves Obesity-Induced Vascular Remodeling by Suppressing NLRP3 Activation // J Cardiovasc Pharmacol. 2019. Vol. 73, N. 5. Р. 326–333. doi: 10.1097/FJC.0000000000000667Belaya ZE, Belova KYu, Biryukova EV, et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021;24(2):4–47. doi: 10.14341/osteo1293Белая Ж.Е., Белова К.Ю., Бирюкова Е.В., и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза // Остеопороз и остеопатии. 2021. Т. 24, № 2. С. 4–47. doi: 10.14341/osteo1293Curtis E, Litwic A, Cooper C, et al. Determinants of Muscle and Bone Aging. J Cell Physiol. 2015;230(11):2618–2625. doi: 10.1002/jcp.25001Curtis E., Litwic A., Cooper C., et al. Determinants of Muscle and Bone Aging // J Cell Physiol. 2015. Vol. 230, N. 11. Р. 2618–2625. doi: 10.1002/jcp.25001Lloyd BD, Williamson DA, Singh NA, et al. Recurrent and injurious falls in the year following hip fracture: a prospective study of incidence and risk factors from the Sarcopenia and Hip Fracture study. J Gerontol A Biol Sci Med Sci. 2009;64(5):599–609. doi: 10.1093/gerona/glp003Lloyd B.D., Williamson D.A., Singh N.A., et al. Recurrent and injurious falls in the year following hip fracture: a prospective study of incidence and risk factors from the Sarcopenia and Hip Fracture study // J Gerontol A Biol Sci Med Sci. 2009. Vol. 64, N. 5. Р. 599–609. doi: 10.1093/gerona/glp003Pajarinen J, Lin T, Gibon E, et al. Mesenchymal stem cell-macrophage crosstalk and bone healing. Biomaterials. 2019;196:80–89. doi: 10.1016/j.biomaterials.2017.12.025Pajarinen J., Lin T., Gibon E., et al. Mesenchymal stem cell-macrophage crosstalk and bone healing // Biomaterials. 2019. Vol. 196. Р. 80–89. doi: 10.1016/j.biomaterials.2017.12.025Raggatt LJ, Wullschleger ME, Alexander KA, et al. Fracture healing via periosteal callus formation requires macrophages for both initiation and progression of early endochondral ossification. Am J Pathol. 2014;184(12):3192–3204. doi: 10.1016/j.ajpath.2014.08.017Raggatt L.J., Wullschleger M.E., Alexander K.A., et al. Fracture healing via periosteal callus formation requires macrophages for both initiation and progression of early endochondral ossification // Am J Pathol. 2014. Vol. 184, N. 12. Р. 3192–3204. doi: 10.1016/j.ajpath.2014.08.017Sebastián C, Herrero C, Serra M, et al. Telomere shortening and oxidative stress in aged macrophages results in impaired STAT5a phosphorylation. J Immunol. 2009;183(4):2356–2364. doi: 10.4049/jimmunol.0901131Sebastián C., Herrero C., Serra M., et al. Telomere shortening and oxidative stress in aged macrophages results in impaired STAT5a phosphorylation // J Immunol. 2009. Vol. 183, N. 4. Р. 2356–2364. doi: 10.4049/jimmunol.0901131Vi L, Baht GS, Soderblom EJ, et al. Macrophage cells secrete factors including LRP1 that orchestrate the rejuvenation of bone repair in mice. Nat Commun. 2018;9(1):5191. doi: 10.1038/s41467-018-07666-0Vi L., Baht G.S., Soderblom E.J., et al. Macrophage cells secrete factors including LRP1 that orchestrate the rejuvenation of bone repair in mice // Nat Commun. 2018. Vol. 9, N. 1. Р. 5191. doi: 10.1038/s41467-018-07666-0Saul D, Khosla S. Fracture healing in the setting of endocrine diseases, aging, and cellular senescence. Endocr Rev. 2022;43(6):984–1002. doi: 10.1210/endrev/bnac008Saul D., Khosla S. Fracture healing in the setting of endocrine diseases, aging, and cellular senescence // Endocr Rev. 2022. Vol. 43, N. 6. Р. 984–1002. doi: 10.1210/endrev/bnac008Topolyanskaya SV. Interleukin 6 in aging and age-related diseases. Klinitsist. 2020;14(3–4):K633. doi: 10.17650/1818-8338-2020-14-3-4-К633Тополянская С.В. Роль интерлейкина 6 при старении и возрастассоциированных заболеваниях // Клиницист. 2020. Т. 14, № 3–4. С. К633. doi: 10.17650/1818-8338-2020-14-3-4-К633Ballesteros J, Rivas D, Duque G. The role of the kynurenine pathway in the pathophysiology of frailty, sarcopenia, and osteoporosis. Nutrients. 2023;15(14):3132. doi: 10.3390/nu15143132Ballesteros J., Rivas D., Duque G. The role of the kynurenine pathway in the pathophysiology of frailty, sarcopenia, and osteoporosis // Nutrients. 2023. Vol. 15, N. 14. Р. 3132. doi: 10.3390/nu15143132Ge Y, Huang M, Yao YM. Recent advances in the biology of IL-1 family cytokines and their potential roles in development of sepsis. Cytokine Growth F R. 2019;45:24–34. doi: 10.1016/j.cytogfr.2018.12.004Ge Y., Huang M., Yao Y.M. Recent advances in the biology of IL-1 family cytokines and their potential roles in development of sepsis // Cytokine Growth F R. 2019. Vol. 45. Р. 24–34. doi: 10.1016/j.cytogfr.2018.12.004Jiang N, An J, Yang K, et al. NLRP3 inflammasome: A new target for prevention and control of osteoporosis? Front Endocrinol (Lausanne). 2021;12:752546. doi: 10.3389/fendo.2021.752546Jiang N., An J., Yang K., et al. NLRP3 inflammasome: A new target for prevention and control of osteoporosis? // Front Endocrinol (Lausanne). 2021. Vol. 12. Р. 752546. doi: 10.3389/fendo.2021.752546Fischer J, Hans D, Lamy O, et al. "Inflammaging" and bone in the OsteoLaus cohort. Immun Ageing. 2020;17:5. doi: 10.1186/s12979-020-00177-xFischer J., Hans D., Lamy O., et al. "Inflammaging" and bone in the OsteoLaus cohort // Immun Ageing. 2020. Vol. 17. Р. 5. doi: 10.1186/s12979-020-00177-xZhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644–658. doi: 10.1111/acel.12344Zhu Y., Tchkonia T., Pirtskhalava T., et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs // Aging Cell. 2015. Vol. 14, N. 4. Р. 644–658. doi: 10.1111/acel.12344Morgunova GV, Khokhlov AN. Drugs with senolytic activity: prospects and possible limitations. Vestnik Moskovskogo universiteta. Seriya 16. Biologiya. 2023;78(4):278–284. doi: 10.55959/MSU0137-0952-16-78-4-3Моргунова Г.В., Хохлов А.Н. Препараты с сенолитической активностью: перспективы и возможные ограничения // Вестник Московского университета. Серия 16. Биология. 2023. Т. 78, № 4. С. 278–284. doi: 10.55959/MSU0137-0952-16-78-4-3Toldo S, Mezzaroma E, Buckley LF, et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther. 2022; 236:108053. doi: 10.1016/j.pharmthera.2021.108053Toldo S., Mezzaroma E., Buckley L.F., et al. Targeting the NLRP3 inflammasome in cardiovascular diseases // Pharmacol Ther. 2022. Vol. 236. Р. 108053. doi: 10.1016/j.pharmthera.2021.108053Solomon SD, McMurray JJV, Anand IS, et al. Investigators and committees. angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–1620. doi: 10.1056/NEJMoa1908655Solomon S.D., McMurray J.J.V., Anand I.S., et al. Investigators and committees. angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction // N Engl J Med. 2019. Vol. 381, N. 17. Р. 1609–1620. doi: 10.1056/NEJMoa1908655Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364–376. doi: 10.1016/S0140-6736(18)32112-3Compston J.E., McClung M.R., Leslie W.D. Osteoporosis // Lancet. 2019. Vol. 393, N. 10169. Р. 364–376. doi: 10.1016/S0140-6736(18)32112-3